Antiangiog%C3%A8nicAntiangiogeneseAngiogenesis_inhibitorAntiangiog%C3%A9nico%D8%A8%D8%A7%D8%B2%D8%AF%D8%A7%D8%B1%D9%86%D8%AF%D9%87_%D8%B1%DA%AF%E2%80%8C%D8%B2%D8%A7%DB%8C%DB%8CPerencat_angiogenesisAngiogeneseremmer%D0%90%D0%BD%D0%B3%D0%B8%D0%BE%D0%B3%D0%B5%D0%BD%D0%BD%D1%8B%D0%B9_%D0%B8%D0%BD%D0%B3%D0%B8%D0%B1%D0%B8%D1%82%D0%BE%D1%80Inhibitori_angiogenezeInhibitori_angiogenezeAngiogenesh%C3%A4mmare%E0%B8%AA%E0%B8%B2%E0%B8%A3%E0%B8%A2%E0%B8%B1%E0%B8%9A%E0%B8%A2%E0%B8%B1%E0%B9%89%E0%B8%87%E0%B8%81%E0%B8%B3%E0%B9%80%E0%B8%99%E0%B8%B4%E0%B8%94%E0%B8%AB%E0%B8%A5%E0%B8%AD%E0%B8%94%E0%B9%80%E0%B8%A5%E0%B8%B7%E0%B8%AD%E0%B8%94Q574834
about
Prevention of medication-related osteonecrosis of the jaws secondary to tooth extractions. A systematic reviewEfficacy and safety of widely used treatments for macular oedema secondary to retinal vein occlusion: a systematic review.A meta-analysis of the effect of a dexamethasone intravitreal implant versus intravitreal anti-vascular endothelial growth factor treatment for diabetic macular edema.A Phase 1B Dose-escalation and Phase 2a Study of Carotuximab (TRC105) in Combination With Pazopanib in Patients With Advanced Soft Tissue SarcomaCombined administration of PTX and S-HM-3 in TPGS/Solutol micelle system for oncotarget therapyPredictive Score For Maxillary Osteonecrosis After Invasive Oral Surgery
P921
Q120199-0D79EF80-4582-42E1-ABD1-EA36936396B4Q15427852-DAF3F0E5-C831-49A4-AA24-96DA990BA0C4Q203174-E02F2DBB-8420-4878-9E8B-789E59EDE10BQ21116079-A651BBF8-DC67-4B6A-99C3-BAFDD197C7DEQ21396219-9AED50A5-EE9D-4A83-A0B4-A261541805B9Q2409681-E2444565-5023-4F6A-B857-3A8198D52B58Q27088030-3226DF0A-3497-42F1-850B-3FBFEE431F8AQ27097825-0AED94A8-2635-44D8-A15D-001D000B4CDEQ27287834-A0F93FFB-3263-46F8-B0FA-095C92C78BADQ4132745-4381AB47-9605-4DAF-B415-F53A82EE4E9AQ413299-60CE64B3-0AE5-49EB-83D6-E2336D0150E5Q414270-B942F726-EE6E-42FA-AC5C-67CC94157871Q417542-AB7F8462-F3A5-4BD4-AA0D-04596AEAD505Q425681-06BFD910-62C3-4B4C-9051-C87817F48B88Q4884554-442167BB-8063-4F4D-A2F9-EFADBDF4396EQ5201338-B4AA1226-D46D-4FA8-A6EF-67BE0194EC15Q7089373-0ABEC59A-F1AC-4DD7-90B3-4A75C7CE6FBFQ7227206-78F09990-969C-42FA-8BD0-8986061394EFQ7449140-D5883BB1-B5B9-41D9-B4FF-812778F850D8Q7940537-A830556F-4708-4763-BF3F-38BD8C036556Q964482-03C09BD2-5488-410E-8E7D-22A5C2936CF9
P2868
description
agent and endogenous substance ...... velopment of new blood vessels
@en
agente químico o biológico que ...... partir de vasos preexistentes
@es
name
Antiangiogenese
@de
Antiangiogènic
@ca
Inhibitori angiogeneze
@sh
Inhibitori angiogeneze
@sr
Perencat angiogenesis
@ms
angiogenesehemmar
@nn
angiogeneseremmer
@nl
angiogeneshämmare
@sv
angiogenesis inhibitor
@en
antiangiogénico
@es
type
label
Antiangiogenese
@de
Antiangiogènic
@ca
Inhibitori angiogeneze
@sh
Inhibitori angiogeneze
@sr
Perencat angiogenesis
@ms
angiogenesehemmar
@nn
angiogeneseremmer
@nl
angiogeneshämmare
@sv
angiogenesis inhibitor
@en
antiangiogénico
@es
altLabel
Angiogenese-Inhibitor
@de
Angiogeneseonderdrukker
@nl
Angiogenetic Antagonists
@en
Angiogenetic Inhibitors
@en
Angiogenic Antagonists
@en
Angiogenic Inhibitors
@en
Angiostatic Agents
@en
Antagonists, Angiogenic
@en
Anti-Angiogenetic Agents
@en
Anti-Angiogenic Drugs
@en
prefLabel
Antiangiogenese
@de
Antiangiogènic
@ca
Inhibitori angiogeneze
@sh
Inhibitori angiogeneze
@sr
Perencat angiogenesis
@ms
angiogenesehemmar
@nn
angiogeneseremmer
@nl
angiogeneshämmare
@sv
angiogenesis inhibitor
@en
antiangiogénico
@es
P279
P672
P486
P6366
P646
P683
P1417
science/angiogenesis-inhibitor
P373
Angiogenesis inhibitors
P3827
angiogenesis-inhibitors
P486
P6366
2776056115
2909782065
P646
P672
D27.505.696.377.077.099
D27.505.696.377.450.100
D27.505.954.248.025